Psychiatry and Neurology, Neurology · Bedford, TX
NPI
1346404803
Since 2008
Specialty
Psychiatry and Neurology, Neurology
Code 2084N0400X
Group practices
2
Medicare group memberships
Hospitals
3
Hospital affiliations
1305 Airport Fwy Ste 205
Bedford, TX, 76021
Phone (817) 267-6290
Groups this clinician bills Medicare through
Medicare paid, 2024
$197K
17,073 services
Medicare patients, 2024
507
Average age 75
Drug cost, 2024
$1.1M
3,660 prescriptions
Company payments, 2025
$3,786
From 39 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Syed A Hussain was code J0585 (injection, onabotulinumtoxina, 1 unit), 12,700 times for 28 patients. In total Syed A Hussain billed 17,073 services in 31 codes, and Medicare paid $197K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2025-09-16.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0585 Injection, onabotulinumtoxina, 1 unit | Office | 12,700 | 28 | $4.98 | $63K |
| 99214 Office E&M - Established | Office | 706 | 395 | $87.50 | $62K |
| 96127 Behavioral Health Services | Office | 197 | 190 | $3.60 | $709 |
| 99204 Office E&M - New | Office | 194 | 194 | $117.70 | $23K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 61 | 48 | $12.81 | $781 |
| 99213 Office E&M - Established | Office | 54 | 41 | $63.67 | $3,438 |
| 64616 Musculoskeletal | Office | 50 | 23 | $146.68 | $7,334 |
| 95983 Electrical Nerve Conductivity | Office | 26 | 11 | $37.24 | $968 |
| 99215 Office E&M - Established | Office | 17 | 15 | $115.03 | $1,956 |
By year: 2022 $101K for 4,688 services; 2023 $168K for 9,844 services; 2024 $197K for 17,073 services.
Medicare prescription drug claims, 2024
In 2024, the drug Syed A Hussain prescribed most often to Medicare patients was Carbidopa-Levodopa (Carbidopa/Levodopa), with 869 prescriptions and refills. In total Syed A Hussain wrote 3,660 Medicare prescriptions that cost $1.1M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Carbidopa-Levodopa Carbidopa/Levodopa | 869 | 2,191 | 242 | $26K |
| Primidone Generic | 496 | 1,350 | 164 | $20K |
| Carbidopa-Levodopa Er Carbidopa/Levodopa | 400 | 1,103 | 141 | $10K |
| Propranolol Hcl Generic | 255 | 679 | 93 | $5,672 |
| Donepezil Hcl Generic | 233 | 675 | 106 | $2,792 |
| Gabapentin Generic | 230 | 546 | 84 | $3,537 |
| Memantine Hcl Generic | 124 | 331 | 46 | $4,102 |
| Rytary Carbidopa/Levodopa | 99 | 193 | 25 | $144K |
| Topiramate Generic | 98 | 233 | 34 | $857 |
| Clonazepam Generic | 69 | 147 | 27 | $758 |
| Tizanidine Hcl Generic | 63 | 88 | 17 | $541 |
| Nuplazid Pimavanserin Tartrate | 44 | 62 | Under 11 | $300K |
| Sumatriptan Succinate Generic | 43 | 46 | 16 | $411 |
| Pramipexole Dihydrochloride Pramipexole Di-Hcl | 38 | 88 | Under 11 | $495 |
| Pregabalin Generic | 37 | 94 | 16 | $2,582 |
Brand drugs: 237 claims; generic drugs: 3,423 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Syed A Hussain $3,786 ($3,786 in general payments such as food, travel and fees) from 39 companies. The largest payer was Abbvie Inc. with $985.
| Company | Payments | Amount |
|---|---|---|
| Abbvie Inc. ABBV | 47 | $985 |
| Biogen, Inc. BIIB | 18 | $349 |
| Neurocrine BioSciences, Inc. NBIX | 10 | $232 |
| Amneal Pharmaceuticals LLC AMRX | 14 | $228 |
| Eisai Inc. 4523.T | 7 | $214 |
| EMD Serono, Inc. MRK.DE | 20 | $200 |
| Teva Pharmaceuticals USA, Inc. TEVA | 4 | $178 |
| Pfizer Inc. PFE | 8 | $143 |
| Genentech USA, Inc. ROG.SW | 6 | $112 |
| Abbott Laboratories ABT | 2 | $100 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.